Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Generic Drug First-Cycle Approval Rates Lagging Under GDUFA I

Executive Summary

Only 8% of original ANDAs submitted in the user fee program’s third year were approved on the first cycle, compared with 72% that received a complete response letter.


Related Content

Generic Application Quality Showing Signs Of Improvement
ANDA Submission Wave Continues; Is A Crest Near?
Another ANDA Submission Surge Begins
FDA Aims To 'Pierce The Rhetoric' On Generic Application Backlog
Generic User Fee Renewal Talks Faced 'Buyer's Remorse' From GDUFA I
Complex ANDAs To Be Allowed Pre-Submission Product Meetings